NCT07233018

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia

A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: MEI HENG · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Detailed description

This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, efficacy, and cellular pharmacokinetics of CT0991 in patients with relapsed or refractory acute myeloid leukemia. It is planned to enroll 3-24 participants in this trial.

Conditions

• Relapsed/Refractory Acute Myeloid Leukemia(AML)

Interventions

Type	Name	Description
DRUG	CT0991 CAR-T cells infusicn	CAR-T cells# chimeric antigen receptor T cells#

Timeline

• Start date: 2025-11-18
• Primary completion: 2026-06-30
• Completion: 2027-05-30
• First posted: 2025-11-18
• Last updated: 2025-11-18

Locations

1 site across 1 country: China